Could choosing risdiplam instead of nusinersen in the treatment of type 1 spinal muscular atrophy be a huge cost-minimization opportunity?

Skip to the main content

Croatian Medical Journal, Vol. 65 No. 5, 2024.

Essays

https://doi.org/10.3325/cmj.2024.65.454

Could choosing risdiplam instead of nusinersen in the treatment of type 1 spinal muscular atrophy be a huge cost-minimization opportunity?

Andrej Belančić orcid.org/0000-0001-7848-6600 ; Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, Rijeka, Croatia *
Andrea Katrin Faour ; Vancouver Coastal Health, Vancouver, BC, Canada
Elvira Meni Maria Gkrinia ; Independent Researcher, Athens, Greece
Dinko Vitezić ; Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, Rijeka, Croatia

* Corresponding author.

Full text: croatian pdf 81 Kb

page 454-456

downloads: 146

APA 6th Edition

Belančić, A., Faour, A.K., Gkrinia, E.M.M. & Vitezić, D. (2024). Could choosing risdiplam instead of nusinersen in the treatment of type 1 spinal muscular atrophy be a huge cost-minimization opportunity?. Croatian Medical Journal, 65 (5), 454-456. https://doi.org/10.3325/cmj.2024.65.454

MLA 8th Edition

Belančić, Andrej, et al. "Could choosing risdiplam instead of nusinersen in the treatment of type 1 spinal muscular atrophy be a huge cost-minimization opportunity?." Croatian Medical Journal, vol. 65, no. 5, 2024, pp. 454-456. https://doi.org/10.3325/cmj.2024.65.454. Accessed 20 Jul. 2026.

Chicago 17th Edition

Belančić, Andrej, Andrea Katrin Faour, Elvira Meni Maria Gkrinia and Dinko Vitezić. "Could choosing risdiplam instead of nusinersen in the treatment of type 1 spinal muscular atrophy be a huge cost-minimization opportunity?." Croatian Medical Journal 65, no. 5 (2024): 454-456. https://doi.org/10.3325/cmj.2024.65.454

Harvard

Belančić, A., et al. (2024). 'Could choosing risdiplam instead of nusinersen in the treatment of type 1 spinal muscular atrophy be a huge cost-minimization opportunity?', Croatian Medical Journal, 65(5), pp. 454-456. https://doi.org/10.3325/cmj.2024.65.454

Vancouver

Belančić A, Faour AK, Gkrinia EMM, Vitezić D. Could choosing risdiplam instead of nusinersen in the treatment of type 1 spinal muscular atrophy be a huge cost-minimization opportunity?. Croat Med J. [Internet]. 2024 [cited 2026 July 20];65(5):454-456. https://doi.org/10.3325/cmj.2024.65.454

IEEE

A. Belančić, A.K. Faour, E.M.M. Gkrinia and D. Vitezić, "Could choosing risdiplam instead of nusinersen in the treatment of type 1 spinal muscular atrophy be a huge cost-minimization opportunity?", Croatian Medical Journal, vol.65, no. 5, pp. 454-456, 2024. [Online]. https://doi.org/10.3325/cmj.2024.65.454

Abstract

Keywords

Hrčak ID:

336581

URI

https://hrcak.srce.hr/336581

Publication date:

15.10.2024.

Visits: 365 *